NN6435-4697 (Completed)
Dose response and safety of an oral PCSK9-i, NNC0385-0434, in patients with very high or high cardiovascular risk on maximally tolerated statin treatment requiring further LDL-C reduction
- Medicine
- NNC0385-0434 (oraal PCSK9-i)
- Population
- ASCVD
- Phase
- II
- Starting year
- 2020